Skip to main content
CELU
NASDAQ Life Sciences

Celularity Settles Default Claims with Helena for $1M Cash and $2.5M Note Assignment

Analysis by Wiseek AI
Sentiment info
Neutral
Importance info
8
Price
$0.991
Mkt Cap
$28.685M
52W Low
$0.71
52W High
$4.35
Market data snapshot near publication time

Summary

Celularity Inc. has entered into a settlement agreement with Helena Global Investment Opportunities 1 Ltd. to resolve existing claims and a prior event of default, involving $1 million in cash payments and the assignment of a $2.5 million promissory note.


Key Events

  • Settlement of Default

    Celularity resolved existing claims and a prior event of default with Helena Global Investment Opportunities 1 Ltd., which had previously exchanged preferred stock for a convertible note and issued a default notice (as disclosed in an 8-K on April 21, 2026).

  • Financial Terms

    The settlement includes an immediate $500,000 cash payment, five subsequent monthly payments of $100,000 each (totaling $1 million), and the assignment of a $2.5 million promissory note from NEXGEL, Inc. to Helena.

  • Restructured Obligations

    Helena surrendered its Series A Convertible Preferred Stock, and the company's new payment obligations are secured by an amended security agreement, replacing the prior defaulted note.


Analysis

This settlement is a critical step for Celularity, which recently disclosed "going concern" issues and faced a default notice from Helena Global Investment Opportunities 1 Ltd. While the company is committing $1 million in cash and assigning a $2.5 million promissory note, the resolution of this significant financial dispute removes a major overhang and potential legal action, providing much-needed stability. The assignment of the NEXGEL note means Celularity will not receive those future payments directly, but it eliminates a problematic preferred stock and note obligation. This action follows the company's recent 10-K filing to regain Nasdaq compliance, suggesting a concerted effort to address financial challenges.

At the time of this filing, CELU was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.7M. The 52-week trading range was $0.71 to $4.35. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CELU - Latest Insights

CELU
May 28, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
8
CELU
May 01, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
CELU
Apr 22, 2026, 10:16 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
CELU
Apr 21, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
9
CELU
Apr 03, 2026, 11:08 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
CELU
Mar 10, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
9
CELU
Mar 05, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
7
CELU
Jan 21, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
CELU
Jan 08, 2026, 6:15 AM EST
Filing Type: 424B3
Importance Score:
9